DOAC Dosing in CKD/ESRD: Apixaban Leads, But the Evidence Is Thin

Cardiology / Anticoagulation 1 source · Updated Aug 4, 2026

A pharmacist's guide to DOAC selection, dosing, and the inappropriate dose reduction problem in renal impairment.

Bottom Line

Apixaban is the preferred DOAC for patients with advanced CKD and ESRD on dialysis due to its lowest renal elimination (27%), but the supporting evidence remains limited to pharmacokinetic studies and observational data rather than RCTs.

State of Play

DOACs have largely replaced warfarin for stroke prevention in atrial fibrillation, but their use in advanced CKD (CrCl <25-30 mL/min) and ESRD on dialysis remains a clinical gray zone with limited high-quality evidence.

Evidence at a Glance

Source	Key finding	Grade / Verdict
DOAC Dosing in CKD/ESRD: Apixaban Leads, But the Evidence Is Thin Study · PharmD Signal Reference Card	—

🔒

Practice Recommendations: Subscribers Only

The bedside actions and open questions that turn this evidence into practice.

Practice Considerations: the bedside actions

Open Questions & evidence gaps

Want the full review?

Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.

Become a Subscriber →

reference-card

🎓

Synthesized and reviewed by a licensed pharmacist

Each topic review is built from our published deep analyses and checked for clinical accuracy before it goes live.

Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.

Thanks for the feedback!

← Back to Hot Topics